CIK 0001980845 · <br>Emerging growth company
enGene Therapeutics Inc.
Sign in to watch- Ticker
- ENGN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Oct 31
- Incorporated
- Canada (Federal Level)
- Entity type
- operating
- Phone
- (514) 332-4888
- Business address
- 4868 RUE LEVY, SUITE 220, SAINT-LAURENT, Quebec, Canada
- Former names
- enGene Holdings Inc.
Securities
- ENGN Common Stock Nasdaq
- ENGNW Warrants Nasdaq
- Open-market buys, last 90 days
- $10,051
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$10,051. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-28 | Glickman Richard M Director | Option exercise · Stock Option (Right to Buy) | −120 | 0 | ||
| 2024-04-22 | FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC 10% owner | Sale | −47,854 | $15.00 | $718K | 3,036,153 |
| 2024-04-19 | FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC 10% owner | Sale | −100 | $15.00 | $2K | 3,084,007 |
| 2024-04-18 | FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC 10% owner | Sale | −4,575 | $15.01 | $69K | 3,084,107 |
| 2024-03-21 | Zoth Lota S. Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-03-18 | CHEUNG ANTHONY TZEYEW Chief Technology Officer | Option exercise | +52,940 | $0.89 | $47K | 102,873 |
| 2024-03-18 | CHEUNG ANTHONY TZEYEW Chief Technology Officer | Option exercise · Stock Option (Right to Buy) | −52,940 | 0 | ||
| 2024-03-15 | Giguere Lee Chief Legal Ofc. and Corp Secy | Grant or award · Stock Option (Right to Buy) | +225,000 | 225,000 | ||
| 2024-02-20 | BRUNK GERALD A Director | Grant or award | +644,965 | $10.00 | $6.4M | 993,651 |
| 2024-02-20 | BRUNK GERALD A Director | Grant or award | +155,035 | $10.00 | $1.6M | 238,851 |
| 2024-02-20 | Lumira Capital Investment Management Inc. 10% owner | Grant or award | +644,965 | $10.00 | $6.4M | 993,651 |
| 2024-02-20 | Lumira Capital Investment Management Inc. 10% owner | Grant or award | +155,035 | $10.00 | $1.6M | 238,851 |
| 2023-12-29 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Purchase | +400 | $8.30 | $3K | 2,008,200 |
| 2023-12-29 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Purchase | +9,620 | $9.09 | $87K | 2,017,820 |
| 2023-12-28 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Purchase | +5,050 | $7.69 | $39K | 2,007,800 |
| 2023-12-27 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Purchase | +2,750 | $7.17 | $20K | 2,002,750 |
| 2023-11-30 | BRYCE RICHARD PAUL Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +153,000 | 153,000 | ||
| 2023-11-30 | Daws D. Ryan Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +232,000 | 232,000 | ||
| 2023-10-31 | Forbion Growth Sponsor FEAC I B.V. 10% owner | Other acquisition | +130,085 | 1,503,581 | ||
| 2023-10-31 | Forbion Growth Sponsor FEAC I B.V. 10% owner | Other acquisition | +2,262,351 | 3,765,932 |
Page 4 of 7 · 121 trades